Iterum Therapeutics (ITRM) Competitors $0.92 -0.04 (-3.80%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.92 +0.01 (+0.76%) As of 05/21/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM vs. MOLN, RNAZ, DERM, SLN, KRRO, ACRS, FATE, EPRX, IKT, and GLSIShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Molecular Partners (MOLN), TransCode Therapeutics (RNAZ), Journey Medical (DERM), Silence Therapeutics (SLN), Korro Bio (KRRO), Aclaris Therapeutics (ACRS), Fate Therapeutics (FATE), Eupraxia Pharmaceuticals (EPRX), Inhibikase Therapeutics (IKT), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. Molecular Partners TransCode Therapeutics Journey Medical Silence Therapeutics Korro Bio Aclaris Therapeutics Fate Therapeutics Eupraxia Pharmaceuticals Inhibikase Therapeutics Greenwich LifeSciences Molecular Partners (NASDAQ:MOLN) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Does the MarketBeat Community believe in MOLN or ITRM? Iterum Therapeutics received 129 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 63.11% of users gave Iterum Therapeutics an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote. CompanyUnderperformOutperformMolecular PartnersOutperform Votes1348.15% Underperform Votes1451.85% Iterum TherapeuticsOutperform Votes14263.11% Underperform Votes8336.89% Do analysts prefer MOLN or ITRM? Molecular Partners presently has a consensus price target of $12.00, indicating a potential upside of 203.03%. Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 882.53%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, MOLN or ITRM? Molecular Partners has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Which has better earnings and valuation, MOLN or ITRM? Iterum Therapeutics has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolecular Partners$2.23M71.63-$69.04M-$1.92-2.06Iterum TherapeuticsN/AN/A-$24.77M-$0.99-0.93 Is MOLN or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Molecular Partners' net margin of -1,043.01%. Iterum Therapeutics' return on equity of 0.00% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Molecular Partners-1,043.01% -39.31% -35.46% Iterum Therapeutics N/A N/A -90.85% Does the media favor MOLN or ITRM? In the previous week, Molecular Partners had 9 more articles in the media than Iterum Therapeutics. MarketBeat recorded 10 mentions for Molecular Partners and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.47 beat Molecular Partners' score of 0.43 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of MOLN or ITRM? 26.5% of Molecular Partners shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryIterum Therapeutics beats Molecular Partners on 11 of the 17 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.64M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.708.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book-7.636.466.794.50Net Income-$24.77M$143.98M$3.23B$248.18M7 Day Performance-1.34%2.03%1.53%0.20%1 Month Performance-17.48%4.11%10.05%12.37%1 Year Performance-35.49%-2.87%16.71%7.04% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.2454 of 5 stars$0.92-3.8%$9.00+882.5%-35.0%$36.64MN/A-0.7010MOLNMolecular Partners1.9444 of 5 stars$3.93+2.4%$12.00+205.0%+10.6%$158.84M$4.97M-1.83180Earnings ReportAnalyst RevisionRNAZTransCode Therapeutics2.2611 of 5 stars$6.70-17.9%$280.00+4,079.1%-100.0%$156.39MN/A0.009Positive NewsEarnings ReportHigh Trading VolumeDERMJourney Medical2.1051 of 5 stars$6.75-2.6%$9.88+46.3%+101.2%$155.95M$56.13M-7.1890News CoverageEarnings ReportAnalyst RevisionSLNSilence Therapeutics3.525 of 5 stars$4.96+13.5%$33.83+582.1%-78.5%$148.45M$27.70M-3.16100Positive NewsKRROKorro Bio1.9902 of 5 stars$15.71+4.0%$102.43+552.0%-70.9%$147.53M$4.82M-1.6670Analyst RevisionGap UpACRSAclaris Therapeutics2.8661 of 5 stars$1.30-0.8%$10.00+669.2%+9.3%$140.77M$17.78M-2.50100Gap UpFATEFate Therapeutics4.3494 of 5 stars$1.22+14.0%$4.14+239.6%-68.4%$139.82M$13.34M-0.74550EPRXEupraxia Pharmaceuticals2.2038 of 5 stars$3.90+1.6%$10.50+169.2%+32.3%$139.81MN/A-5.4229Gap UpIKTInhibikase Therapeutics1.5002 of 5 stars$1.87-7.0%$6.50+247.6%+4.2%$139.02M$260,000.00-0.706News CoverageGap DownGLSIGreenwich LifeSciences1.1962 of 5 stars$10.18+4.5%$39.00+283.1%-28.1%$135.13MN/A-12.723Earnings Report Related Companies and Tools Related Companies Molecular Partners Alternatives TransCode Therapeutics Alternatives Journey Medical Alternatives Silence Therapeutics Alternatives Korro Bio Alternatives Aclaris Therapeutics Alternatives Fate Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Inhibikase Therapeutics Alternatives Greenwich LifeSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITRM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITRM Stock Free ITRM Stock Alerts